What is the ALX 0600?

ALX 0600 is , while it's Molecular Formula is C164H252N44O55S. Treatmentof intestinal diseases characterized by chemical orsurgical damage of the intestinal epithelium such as ShortBowel Syndrome (SBS) or damage to the intestinalepithelium due to disease (glucagon-like peptide-2 (GLP-2) analog).

What is the CAS number for ALX 0600?

The CAS number of ALX 0600 is 197922-42-2.

What is ALX 0600 (197922-42-2) used for?

Teduglutide was approved in August 2012 by the European Commission and in December 2012 by the US FDA for the treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral nutrition (PN). Teduglutide (also known as ALX-0600) is a GLP-2 analogue in which glycine has been substituted for alanine at position 2 from the N-terminus, thereby conferring resistance to degradation by DPP-4. Teduglutide has similar binding affinity, agonist potency, and agonist efficacy as GLP-2 in assays with the rat GLP-2 receptor. Administration of teduglutide to rats gave a significant increase in small intestine weight and an increase in the height of intestinal villi. Teduglutide was prepared by solid-phase peptide synthesis.

Product classification

Featured Products

Teduglutide

Product Name: Teduglutide
CasNo: 197922-42-2
Purity:
Appearance:

Mobile/Wechat/WhatsApp: +852 61915425

Email:niki@healthtide-api.com

Inquiry

CasNo： 197922-42-2

Molecular Formula： C164H252N44O55S

Factory Supply High Purity Wholesale Teduglutide 197922-42-2 Efficient Transportation

Molecular Formula:C164H252N44O55S
Molecular Weight:3752.13
PSA：1649.52000
LogP:1.01630

Teduglutide(Cas 197922-42-2) Usage

Overview	Teduglutide is a 33-membered polypeptide and a glucagon-like peptide-2 (GLP-2) analog.
Therapeutic Application	Used in the treatment of Short Bowel Syndrome (SBS).
Mechanism of Action	Acts as a GLP-2 analogue, promoting mucosal growth in the intestine. Possible restoration of gastric emptying and secretion.
Pharmacological Effects	Activates GLP-2 receptors in the gut. Stimulates the release of insulin-like growth factor, nitric oxide, and keratinocyte growth factor.
Promoting Repair and Growth	Enhances the repair and normal growth of the intestinal mucosa. Increases villi height and crypt depth in the intestine.

197922-42-2 Relevant articles

Long-Term Outcomes With Teduglutide From a Single Center

Frances Puello MD, Elizabeth Wall RD, Jean Herlitz RN, Edward S. Lozano PharmD, Carol Semrad MD, Dejan Micic MD

, Journal of Parenteral and Enteral Nutrition, Volume45, Issue2 February 2021 Pages 318-322

In a real-world experience, teduglutide therapy results in rapid and sustained reductions in PS. Larger postmarketing studies will be required to reliably predict response to treatment and the factors associated with enteral autonomy.

Teduglutide: A Review in Short Bowel Syndrome

Esther S. Kim & Susan J. Keam

, Drugs, Volume 77, pages 345–352, (2017)

In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a ≥20% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. The proportion of patients who had a reduction in one or more days on PS was also significant with teduglutide compared with placebo.

Home

About us123

Products123

Polypeptide

chemical materials

API

News123

Contact Us123